1 June 2018
WE ARE PLEASE TO ANNOUNCE THAT THE RESULTS OF THE PHASE 1B OF OUR THERAPEUTIC VACCINE DEMONSTRATE AN EXCELLENT SAFETY PROFILE
19 June 2017
We are pleased to annouce the approval of Phase of our Active Targeted Immunotherapy for Myasthenia Gravis by the UZA Ethics Committee on 19 June 2017 and the Belgian and Dutch Regulatory Authorities (May 2017)
19-22 June 2017
Thank you for visiting us Bio 2017 in San Diego on the Belgian Booth and/or meeting us thru One-on-One Partnering
15-17 May 2017
THE PRELIMINARY RESULTS OF THE ONGOING PHASE 1B CLINICAL TRIAL ON PATIENTS OF CV-MG01 VS. PLACEBO DEMONSTRATE SAFETY AND INDICATE EFFICACY AS COMMUNICATED AT THE 13TH INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS AND RELATED DISORDERS AT THE NEW YORK ACADEMY OF SCIENCE ON 16 MAY 2017
7-9 November 2016
Thank you vor visiting us at Bio Europe 2016 in Köln
5-9 June 2016
Thank you for visiting us at Bio 2016 in San Francisco
November 2015
THE PHASE 1B OF CURAVAC’s MG THERAPEUTIC VACCINE STARTED AT THE ANTWERP UNIVERSITY HOSPITAL IN BELGIUM
2-4 November 2015
Thank you for meeting us at Bio Europe 2015 in Munich
October 2015
CuraVac’s MG therapeutic vaccine receives Clinical Trial Authorization (CTA) in Belgium and the Ethical Committee of the University Hospital of Antwerp (UZA) gives its authorization for a Phase 1b trial on 24 to 32 patients.
15-19 June 2015
Thank you for meeting us at Bio 2015 in Philadelphia.
10 December 2014
CURAVAC WON THE BEST PRESENTATION AWARD AT THE EUROPEAN VENTURE CONTEST 2014 (December 2014)
3-5 November 2014
Thank you for meeting us at Bio Europe 2014 in Frankfurt
9 October 2014
CURAVAC WON THE BEST PRESENTATION AWARD AT THE LIFE SCIENCES INVESTMENT FORUM (October 2014)
23-26 June 2014
Thank you for visiting us at Bio 2014 in San Diego on the Belgian Pavilion
6 June 2014
CURAVAC AND THE MYASTERIX PROJECT WON THE AWARD OF THE BEST IMMUNOTHERAPIES & VACCINES PROJECT AT BIOVISION 2014 (June 2014)
June 2014
CuraVac will present the company and the myasterix project at BioVision on June 6th in Lyon, France
April 2014
CuraVac was present at Buzz4Bio
October 2013
CuraVac is proud to announce the start of the Myasterix project.
April 2013
An independent Jury deems the Myasterix project one of the seven best therapeutic vaccine projects and recommends that the European Commission subsidizes the project.
April 2013
CuraVac attends the Bio 2013 convention in Chicago
October 2012
CuraVac creates the Myasterix consortium
June 2012
CuraVac attends the Bio 2012 convention in Boston